Study showed Dutasteride and Docetaxel nanostructured lipid carriers improved hormone levels in prostate cancer, suggesting effective therapy options.
Objectives: This study investigates the impact of NMU-testosterone-induced prostate cancer on serum hormone levels, oxidative stress markers, cytokine profiles, and histological changes in the prostate gland. Additionally, it evaluates the therapeutic potential of Dutasteride Nanostructured Lipid Carriers (Dutasteride NLC) and Docetaxel Nanostructured Lipid Carriers (Docetaxel NLC) in modulating these pathological alterations. Materials and Methods: Male rats were divided into control and experimental groups, with prostate cancer induced using N-methyl-N-nitrosourea (NMU) and testosterone. Serum hormone levels, including testosterone, dihydrotestosterone (DHT), and prostate-specific antigen (PSA), were analyzed. Antioxidant enzyme activities (SOD, catalase, GR, GPx, and reduced glutathione) and lipid peroxidation levels were assessed to determine oxidative stress. Cytokine profiles were evaluated to examine immune dysregulation. Histopathological examination of prostate tissues was conducted to assess morphological alterations. Treatment groups received Dutasteride NLC, Docetaxel NLC, or a combination of both to determine their therapeutic effects. Results: Prostate cancer induction resulted in significant elevations in testosterone, DHT, and PSA levels, indicating hormonal imbalances. Oxidative stress markers showed increased lipid peroxidation and depletion of antioxidant enzymes in the PCa-induced group. Inflammatory cytokine levels were dysregulated, reflecting immune imbalances. Histological analysis revealed high-grade neoplasia, secretory cell proliferation, and stromal hyperplasia in the prostate tissue of cancer-induced rats. Treatment with Dutasteride NLC and Docetaxel NLC reduced hormone levels, restored antioxidant enzyme activity, and normalized cytokine levels. Histopathological examination showed improvements, with reduced neoplasia and stromal cell hyperplasia. Co-administration of Dutasteride NLC and Docetaxel NLC demonstrated superior therapeutic effects, indicating a synergistic action in mitigating cancer-related alterations. Conclusion: This study highlights the potential of Dutasteride NLC and Docetaxel NLC in counteracting prostate cancer-associated hormonal imbalances, oxidative stress, immune dysregulation, and histopathological alterations. The findings suggest a promising role for these nanocarrier-based therapies in prostate cancer management. Further research and clinical investigations are warranted to validate their efficacy in translational applications.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: